Compare · ALMS vs NVO
ALMS vs NVO
Side-by-side comparison of Alumis Inc. (ALMS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.77B, about 75.9x ALMS ($2.59B).
- Over the past year, ALMS is up 517.7% and NVO is down 39.5% - ALMS leads by 557.2 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 7 for ALMS).
- NVO has more recent analyst coverage (25 ratings vs 13 for ALMS).
- Company
- Alumis Inc.
- Novo Nordisk A/S
- Price
- $20.29-6.04%
- $44.05-3.39%
- Market cap
- $2.59B
- $196.77B
- 1M return
- -17.72%
- +4.41%
- 1Y return
- +517.66%
- -39.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 7
- 11
- Recent ratings
- 13
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ALMS
- Chief Medical Officer Drappa Jorn exercised 26,852 shares at a strike of $6.65, increasing direct ownership by 83% to 59,339 units (SEC Form 4)
- SEC Form DEFA14A filed by Alumis Inc.
- SEC Form DEF 14A filed by Alumis Inc.
- Alumis downgraded by H.C. Wainwright with a new price target
- SEC Form 10-Q filed by Alumis Inc.
- Alumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
- SEC Form 4 filed by Foresite Labs, Llc
- SEC Form 4 filed by Foresite Capital Management Vi Llc
- SEC Form 4 filed by Tananbaum James B.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates